India Glycols Ltd

India Glycols Q1 FY27 Results & Demerger Outlook: Spirits, Chemicals & Biopharma Show Growth 🚀

• Q1 FY27 Gross Revenue grew 19% YoY to ₹ 2,988 Cr; Net Revenue up 9% YoY to ₹ 1,130 Cr.

• Q1 FY27 EBITDA increased 13% YoY to ₹ 170 Cr; PAT surged 32% YoY to ₹ 97 Cr.

• Segment performance: Spirits revenue ₹ 361 Cr (+5.3% YoY); Chemicals revenue ₹ 362 Cr (+20.6% YoY); Bio Fuel revenue ₹ 323 Cr; Ennature Biopharma revenue grew 65% YoY.

• Finance Costs declined to ₹ 25 Cr in Q1 FY27 from ₹ 45 Cr in Q1 FY26, aiding profitability.

• Pro-forma Q1 FY27 for demerged entities: IGL Spirits Net Revenue ₹ 694 Cr, EBITDA ₹ 120 Cr (+17% YoY), Margin 17.3%; India Glycols Net Revenue ₹ 345 Cr (+24% YoY), EBITDA ₹ 40 Cr (+12% YoY), Margin 11.6%; Ennature Bio Pharma Net Revenue ₹ 90 Cr (+53% YoY), EBITDA ₹ 10 Cr (+100% YoY), Margin 11.1%.

• Future targets: IGL Spirits aims for FY27 EBITDA > ₹ 500 Cr and ₹ 1,000 Cr in 4-5 years; India Glycols targets FY27 EBITDA > ₹ 200 Cr and ₹ 400 Cr in 4-5 years; Ennature Biopharma aims for FY27 EBITDA > ₹ 50 Cr and ₹ 130-150 Cr in 4-5 years.

• FY26 Consolidated Net Revenue was ₹ 4,211 Cr, with EBITDA of ₹ 654 Cr and PAT of ₹ 293 Cr.